brain_cancer

Epicast: Brain Cancer – Epidemiology Forecast to 2024

pharmafile | April 7, 2017 | News story | Medical Communications, Research and Development brain cancer, pharmafile 

Primary brain cancer is defined as a malignant neoplasm that originates in the central nervous system (CNS), which consists of the brain and spinal cord, including the brain stem (NCI, 2015). The American Brain Tumor Association (ABTA) reports that there are over 120 different types of malignant and benign brain tumours, (ABTA, 2014). The type and severity of a brain tumour is defined by the cells from which the tumour originated, as well as by the proliferative potential of the abnormal growth. Only malignant tumours are designated as cancer (NCI, 2015). Primary brain tumours are those that start in the brain and may, in time, migrate elsewhere in the body, while metastatic brain tumours are those that start elsewhere in the body and migrate to the brain or other parts of the CNS.

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for brain cancer in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of brain cancer, each segmented by sex and age (in 10- year age groups). Additionally, it includes a forecast for the diagnosed incident cases of brain cancer, segmented by type (glioblastoma, meningioma, ependymoma, oligodendroglioma, and CNS lymphoma). This forecast for brain cancer includes only primary malignant brain tumours originating in the CNS (ICD-10 codes C70– C72).

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of brain cancer will increase from 55,084 cases in 2014 to 62,226 cases in 2024, at an Annual Growth Rate (AGR) of 1.30%. The US will have the highest number of diagnosed incident cases of brain cancer among the 7MM throughout the forecast period. The five-year diagnosed prevalent cases of brain cancer are also expected to increase from 84,704 cases in 2014 to 89,984 cases in 2024, at an AGR of 0.62%.

Below mentioned figures (7MM, Diagnosed Incident Cases of Brain Cancer, All Ages, Both Sexes, N, 2014 and 2024 and 7MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, All Ages, Both Sexes, N, 2014 and 2024) present the diagnosed incident cases and the five-year diagnosed prevalent cases of brain cancer in the 7MM in 2014 and 2024, respectively.

 

 

Related Content

top 10

Pharmafile.com’s top 10 news stories of the week

COVID-19 news has slowed down in the last week, allowing different pharma developments to take …

pharmafile_autumn_2020_front_cover

The Autumn 2020 edition of Pharmafile is available to read for free online now!

The Autumn 2020 edition of Pharmafile is available to read for free online now! 2020 …

shutterstock

Scorpion venom added to CAR-T therapy increases efficacy in brain cancer, research shows

Chimeric antigen receptor T cell (CAR-T) therapy has gained much traction and attention in the …

Latest content